Pharmaceuticals Archives

GLENMARK – Glenmark Pharmaceuticals – Q4 FY26 Financial Results – 29-May-26

Glenmark’s FY26 marks inflection — debt‑free, doubled pre‑exceptional profitability, and robust OCF. Risks: +48.5% receivables surge and ₹22,661M exceptional charges cloud earnings quality. If receivables normalize and charges stabilize, ~₹20,873M FCF supports re‑rating; monitor DSO trends, exceptional disclosures, and ₹15,361M non‑current liability build.

1–2 minutes

🔍 Observations

Topline

Net sales surged 27.1% YoY (₹131,458M → ₹167,114M), driven by broad-based geographic expansion and the Ichnos Sciences consolidation effect post-demerger.
Q4FY26 net sales of ₹37,603M grew 16.8% YoY vs Q4FY25’s ₹32,201M, though sequentially softer vs Q3FY26’s ₹38,880M — slight volume moderation at year-end.
Other operating income jumped to ₹2,711M in FY26 vs ₹1,759M in FY25, reflecting licensing/milestone receipts boosting reported revenue quality.

Bottomline

Reported PAT: ₹13,620M in FY26 vs ₹10,471M in FY25 (+30.1% YoY), but exceptional losses of ₹22,661M (vs ₹3,728M prior year) dominate the narrative — pre-exceptional PBT was ₹42,508M vs ₹17,720M (+139.9% YoY), a far stronger underlying picture.
Q4FY26 PAT of ₹3,013M was inflated by negative current tax (refund of ₹301M) — normalized earnings were lower; Q3FY26 PAT of ₹4,032M was cleaner.
Basic EPS: ₹48.26 in FY26 vs ₹37.11 in FY25 — EPS growth understates operational improvement given the drag from escalating exceptional charges.

Margins

EBITDA proxy (pre-exceptional PBT + Finance costs + D&A): ₹42,508M + ₹2,087M + ₹5,735M = ₹50,330M on revenue of ₹169,825M → EBITDA margin ~29.6% in FY26 vs (₹17,720M + ₹2,071M + ₹4,860M) = ₹24,651M on ₹133,217M → 18.5% in FY25. A 1,110 bps margin expansion.
Reported net margin: ₹13,620M / ₹169,825M = 8.0% — depressed by exceptional items; pre-exceptional PBT margin = 25.0%.
Cost of materials + stock-in-trade consumed ₹47,475M (net of inventory changes ₹6,106M) = ₹41,369M effective material cost on ₹167,114M net sales = 24.8% — improved from prior year’s effective ~32.7%.

Growth Trajectory

Revenue CAGR implied (FY25→FY26): +27.1% — sustainable pace uncertain; Ichnos consolidation is a one-time step-up in the base.
Employee costs grew 18.4% YoY (₹30,221M → ₹35,779M) — below revenue growth, indicating early operating leverage.
Other expenses grew 13.6% YoY (₹35,950M → ₹40,848M) — again below revenue growth, reinforcing operating leverage thesis.

SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Earnings Call – 22-May-26

Sun Pharmaceutical Industries’ topline growth hinges on Innovative Medicines and Organon synergies, while margins and EPS are sensitive to cost normalization, tax rates, and execution risks.

1–2 minutes

Also see: SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Financial Results – 22-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Organon integration on track (Q4 FY27), Innovative Medicines growth (15–20% YoY), margin stabilization (27–28% EBITDA).
Outcome: High single-digit topline growth achieved, EPS stable with tax rate at 25%, generics recovery lagging but offset by Innovative Medicines. Semaglutide gains traction in H2 FY27.

DIVISLAB – Divi’s Laboratories – Q4 FY26 Earnings Call – 23-May-26

DIVISLAB/ Divi’s Laboratories’ topline growth remains robust (double-digit) on volume resilience and CS pipeline, but margins are structurally capped (~32%) by pricing pressure and cost inflation; bottomline stability hinges on forex and capex efficiency.

1–2 minutes

Also see: DIVISLAB – Divi’s Laboratories – Q4 FY26 Financial Results – 23-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Double-digit revenue growth sustained via volume stability in generics and gradual CS ramp-up. Margins remain flat at ~32% as RM/freight pressures offset INR benefits. Capex conversion cycle averages 2 years; FY27 capex at ~₹2,000 crores (18% of sales). Forex gains neutralize due to hedging.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Earnings Call – 19-May-26

Zydus Lifesciences’ topline growth hinges on specialty scaling and international momentum, while margins and cash flow are sensitive to US generics competition, acquisition execution, and capex intensity.

1–2 minutes

Also see: ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Management delivers on high-teens revenue growth and >24% EBITDA margins in FY27. US generics decline offset by specialty/international growth, while MedTech/Comfort Click meet guidance. Capex/working capital pressure limits FCF growth, but leverage remains <1x net debt-to-EBITDA. Biosimilar scale-up aligns with FY29–30 timeline.

DIVISLAB – Divi’s Laboratories – Q4 FY26 Financial Results – 23-May-26

Divi’s FY26 delivered topline growth with rare margin expansion in APIs, funded capex doubling via accruals on debt‑free balance sheet. Risks: ₹718 Cr inventory build — demand vs procurement clarity due H1FY27. Strong OCF, accelerating exit rate, and expanding margins keep structural case intact despite FCF compression.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 12.8% YoY (₹9,360 Cr → ₹10,560 Cr), with Q4FY26 at ₹2,831 Cr — the strongest quarter of FY26, up 9.5% over Q4FY25’s ₹2,585 Cr.
Sequential revenue momentum held: Q2→Q3→Q4 progression of ₹2,604 Cr → ₹2,604 Cr → ₹2,831 Cr signals an accelerating exit rate into FY27.
Other income jumped 44% YoY (₹352 Cr → ₹507 Cr), driven by interest on FDs; operationally irrelevant but flatters total income.

Bottomline

Net profit grew 17.2% YoY (₹2,191 Cr → ₹2,568 Cr), outpacing revenue — positive operating leverage at work.
Q4FY26 PAT of ₹751 Cr was the highest quarterly print, up 13.4% over Q4FY25’s ₹662 Cr; sequential jump from ₹583 Cr reflects Q3’s one-time labour code charge of ₹74 Cr normalising out.
Basic EPS expanded from ₹82.53 to ₹96.75 — a 17.2% YoY improvement on an unchanged share count.

Margins

EBITDA (PBT ex-other income + depreciation + finance costs): FY26 = ₹3,462 – ₹507 + ₹463 + ₹23 = ₹3,441 Cr on revenue of ₹10,560 Cr → EBITDA margin 32.6% vs FY25: ₹2,916 – ₹352 + ₹402 + ₹2 = ₹2,968 Cr on ₹9,360 Cr → 31.7%. ~90 bps expansion YoY.
Net profit margin (PAT/Revenue from ops): FY26 = 2,568/10,560 = 24.3% vs FY25 = 2,191/9,360 = 23.4%. ~90 bps improvement.
Employee costs grew 16% YoY (₹1,243 Cr → ₹1,442 Cr) and material costs grew 14.6% (₹3,821 Cr → ₹4,378 Cr net of inventory change: ₹3,821–96 = ₹3,725 Cr FY25 vs ₹4,378–285 = ₹4,093 Cr FY26, +9.9%) — cost discipline preserved margin expansion.

Growth Trajectory

Revenue CAGR trajectory: 12.8% in FY26; combined with margin expansion, the earnings growth of 17.2% YoY demonstrates operating leverage materialising at scale.
CWIP nearly doubled (₹1,022 Cr → ₹2,113 Cr) and capex was ₹2,520 Cr in FY26 vs ₹1,438 Cr in FY25 — a 75% capex step-up signals management’s confidence in sustaining double-digit volume growth.
Total equity grew from ₹14,969 Cr to ₹16,761 Cr, entirely through retained earnings; the asset base expanded from ₹16,932 Cr to ₹20,033 Cr — 18.3% in one year.

SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Financial Results – 22-May-26

Sun Pharma’s FY26 delivered 11% topline growth with ~31.5% EBITDA margins, specialty pivot sustaining quality. PAT up 5% understates strength; underlying trajectory solid. Re‑rating hinges on specialty‑led margin inflection toward 34–35%. Risks: faster opex growth, acquisition integration, intangibles spike, and receivables build.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 11.2% YoY (₹525,784 Mn → ₹584,620 Mn), driven by both domestic formulations and specialty/global generic expansion.
Q4FY26 revenue of ₹146,118 Mn grew 12.8% YoY vs Q4FY25 (₹129,588 Mn), though declined 5.9% QoQ from Q3FY26’s ₹155,205 Mn — seasonal softness, not structural.
Other operating revenues fell sharply (₹5,372 Mn → ₹2,419 Mn YoY), a ₹2,953 Mn headwind to topline largely absorbed by core revenue momentum.

Bottomline

Reported PAT grew 5.0% YoY (₹109,290 Mn → ₹114,794 Mn); adjusted for ₹13,075 Mn of exceptional items in FY26 vs ₹6,779 Mn in FY25, underlying PAT growth is broadly similar.
Tax outflow surged — effective tax rate on reported PBT rose from ~17.4% to ~26.0% — compressing PAT despite strong EBIT growth; a large one-off deferred tax reversal benefited FY25.
EPS grew modestly from ₹45.6 to ₹47.8 (basic), with no dilution — share count flat at ~2,399 Mn shares.

Margins

EBITDA (PBT before exceptional + Finance costs + D&A): FY26 = ₹151,189 + ₹3,389 + ₹29,379 = ₹183,957 Mn on revenue of ₹584,620 Mn → EBITDA margin ~31.5% vs FY25: ₹137,521 + ₹2,314 + ₹25,754 = ₹165,589 Mn on ₹525,784 Mn → 31.5%. Margins held flat despite R&D intensity rising.
Net profit margin: ₹114,794 / ₹584,620 = 19.6% vs ₹109,290 / ₹525,784 = 20.8% — 120 bps compression, driven entirely by tax normalisation.
R&D spend rose to ₹34,741 Mn (5.9% of revenue) vs ₹31,542 Mn (6.0%) — pipeline investment sustained without margin sacrifice.

Growth Trajectory

Three-year revenue compound implied by 11.2% topline growth and consistent specialty mix shift signals durable mid-teens USD revenue CAGR in global markets.
Employee costs grew 14.5% YoY (₹99,731 Mn → ₹114,189 Mn), outpacing revenue — talent investment for specialty scaling, but warrants monitoring.
Other expenses grew 13.3% YoY (₹167,718 Mn → ₹190,083 Mn) — faster than revenue, suggesting operating leverage yet to fully materialise.

TORNTPHARMA – Torrent Pharmaceuticals – Q4 FY26 Financial Results – 22-May-26

Torrent Pharma’s FY26 vaulted revenues past ₹13,900 Cr via acquisition, but net debt/EBITDA ~2.9x and ₹24,280 Cr intangibles suppress PAT. Core remains resilient with ₹2,346 Cr FCF and ~31% EBITDA margins. Re‑rating hinges on brand revenue scaling faster than amortisation; watch receivables and finance costs.

1–2 minutes

🔍 Observations

Topline

Revenue from ops grew 21.4% YoY (₹11,516 Cr → ₹13,980 Cr), reflecting the step-up from an acquired business consolidating into FY26 numbers.
Q4FY26 printed ₹4,197 Cr — +41.8% YoY and +27.1% QoQ — the sharpest quarterly outturn, indicating the full consolidation effect landed in Q4.
Other income turned negative in FY26 (–₹94 Cr vs +₹23 Cr), reflecting forex and hedging losses that clipped reported total income.

Bottomline

Net profit grew 11.9% YoY (₹1,911 Cr → ₹2,138 Cr), well below revenue growth — margin dilution from acquisition-linked D&A and finance costs.
Q4FY26 net profit collapsed to ₹364 Cr vs ₹498 Cr in Q4FY25 (–26.9% YoY), driven by ₹236 Cr finance costs, ₹508 Cr D&A, and ₹66 Cr exceptional charges in a single quarter.
Effective tax rate improved to 25.6% (from 28.5%), providing partial offset; without this, PAT growth would have been thinner still.

Margins

EBITDA margin contracted ~100 bps to 31.3% (FY26) from 32.3% (FY25) — operating leverage partly absorbed by employee cost growth of 21.2% YoY.
Net profit margin compressed 130 bps to 15.3%, squeezed by D&A surging 40.8% and finance costs up 52.8%.
Q4FY26 EBITDA margin held at 31.9% (vs 32.0% in Q4FY25) — the operational core is stable; below-EBITDA lines are where the dilution originates.

Growth Trajectory

Organic revenue growth is likely sub-15%; the headline 21.4% is acquisition-inflated — normalisation will depend on how fast the acquired portfolio integrates.
EPS grew 13.2% (₹56.47 → ₹63.92) despite no equity dilution — share count unchanged at 169.23 Cr shares — all growth is earnings-driven on the legacy base.
D&A will remain elevated for multiple years as ₹24,280 Cr of intangible assets amortise; this is the single biggest structural drag on reported PAT growth.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

Zydus’ FY26 shows EBITDA margin expansion and Pharma EBIT at multi‑year highs, but acquisitions flipped net cash to net debt, collapsed OCF, and added loss‑making Med Tech and Consumer units. FY27 re‑rating hinges on OCF recovery, debt reduction, and margin inflection in new segments.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.8% YoY (₹232,415 Mn → ₹271,484 Mn), led by Pharma (₹205,415 Mn → ₹224,121 Mn, +9.1%) and a near-doubling of Consumer Products (₹26,976 Mn → ₹39,540 Mn, +46.6%).
Medical Technologies contributed ₹7,823 Mn in FY26 vs ₹24 Mn in FY25 — full-year impact of an acquired business.
Q4FY26 revenue of ₹75,870 Mn was up 16.2% YoY vs Q4FY25 (₹65,279 Mn), with sequential improvement from Q3FY26 (₹68,645 Mn).

Bottomline

Net profit grew 11.3% YoY (₹45,255 Mn → ₹50,400 Mn); exceptional items of ₹5,166 Mn (vs ₹2,196 Mn in FY25) weighed on reported PAT.
Pre-exceptional PBT rose 14.3% YoY (₹62,463 Mn → ₹71,377 Mn) — underlying earnings quality remains strong.
Effective tax rate dropped meaningfully: 23.4% in FY26 vs 23.4% in FY25 — stable, no distortion from deferred tax movements at the net level.

Margins

EBITDA proxy (PBT before exceptional + D&A + Finance costs): ₹71,377 + ₹14,080 + ₹4,389 = ₹89,846 Mn on revenue of ₹271,484 Mn → EBITDA margin ~33.1% vs ₹62,463 + ₹9,158 + ₹1,699 = ₹73,320 Mn on ₹232,415 Mn → 31.5% in FY25. ~160 bps expansion YoY.
Net profit margin: ₹50,400 / ₹271,484 = 18.6% vs ₹45,255 / ₹232,415 = 19.5% — 90 bps compression, driven by higher D&A (₹14,080 Mn vs ₹9,158 Mn) and finance costs (₹4,389 Mn vs ₹1,699 Mn) post-acquisitions.
Consumer Products EBIT margin compressed sharply: ₹2,671 / ₹39,540 = 6.8% vs ₹3,470 / ₹26,976 = 12.9% — the acquired business is dilutive at EBIT level.

Growth Trajectory

3-year revenue compounding is intact; FY26’s 16.8% growth is above-industry for a company of this scale.
Pharma segment — the core engine — delivered only 9.1% growth; incremental revenue acceleration depended heavily on acquisitions.
Medical Technologies segment is loss-making (EBIT: -₹1,782 Mn) and rapidly scaling costs — trajectory unclear without further disclosure.

DRREDDY – Dr. Reddy’s Laboratories – Q4 FY26 Earnings Call – 12-May-26

Dr. Reddy’s Laboratories’ topline growth hinges on semaglutide/abatacept execution, bottomline resilience depends on margin recovery via mix shift, and margins face structural pressure without high-margin scale.

1–2 minutes

Also see: DRREDDY – Dr. Reddy’s Laboratories – Q4 FY26 Financial Results – 12-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Semaglutide 10–11M units in FY27 (Brazil delay to FY28) + abatacept launch late CY27. Gross margin ~50%, EBITDA margin ~23–24% as price erosion and SSA drag persist. North America stabilizes but biosimilars scale slowly; FY29 biosimilars sales ~US$500M. EPS growth flat without margin expansion.

CIPLA – name – Q4 FY26 Earnings Call – 13-May-26

CIPLA’s topline growth hinges on U.S. pipeline execution (respiratory/peptides) and India chronic outperformance; margins depend on H2 FY27 launch scale and geopolitical cost containment.

1–2 minutes

Also see: CIPLA – Cipla Ltd – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

U.S. 3/4 respiratory approvals in FY27, Ventolin ramp-up in H2, Lanreotide delayed to FY28. India 10–12% growth. EBITDA margin at 19–20%, $1B U.S. run-rate exit. Geopolitical costs contained; R&D spend at 7% of revenue. Steady capital allocation (R&D > M&A).